XIGDUO XR Drug Patent Profile

Which patents cover Xigduo Xr, and when can generic versions of Xigduo Xr launch?

Xigduo Xr is a drug marketed by Astrazeneca Ab and is included in one NDA. There are five patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and thirty-six patent family members in forty-six countries.

The generic ingredient in XIGDUO XR is dapagliflozin; metformin hydrochloride. There are twenty-six drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the dapagliflozin; metformin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xigduo Xr

A generic version of XIGDUO XR was approved as dapagliflozin; metformin hydrochloride by ALKEM LABS LTD on April 6^th, 2026.

Summary for XIGDUO XR

International Patents:	236
US Patents:	5
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XIGDUO XR

Paragraph IV (Patent) Challenges for XIGDUO XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XIGDUO XR	Extended-release Tablets	dapagliflozin; metformin hydrochloride	2.5 mg/1000 mg	205649	1	2018-10-29
XIGDUO XR	Extended-release Tablets	dapagliflozin; metformin hydrochloride	5 mg/500 mg 5 mg/1000 mg 10 mg/500 mg 10 mg/1000 mg	205649	10	2018-01-08

US Patents and Regulatory Information for XIGDUO XR

XIGDUO XR is protected by five US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	XIGDUO XR	dapagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205649-003	Oct 29, 2014	AB	RX	Yes	No					Y
Astrazeneca Ab	XIGDUO XR	dapagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205649-004	Oct 29, 2014	AB	RX	Yes	Yes
Astrazeneca Ab	XIGDUO XR	dapagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205649-003	Oct 29, 2014	AB	RX	Yes	No					Y
Astrazeneca Ab	XIGDUO XR	dapagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205649-003	Oct 29, 2014	AB	RX	Yes	No					Y
Astrazeneca Ab	XIGDUO XR	dapagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205649-005	Jul 28, 2017	AB	RX	Yes	No					Y
Astrazeneca Ab	XIGDUO XR	dapagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205649-001	Oct 29, 2014	AB	RX	Yes	No					Y

International Patents for XIGDUO XR

When does loss-of-exclusivity occur for XIGDUO XR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Denmark

European Patent Office

Hungary

Japan

Lithuania

Mexico

Norway

Poland

Portugal

Russian Federation

Serbia

Slovenia

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XIGDUO XR around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	026024	COMPUESTOS INHIBIDORES SGLT2 DE GLUCOSIDOS DE C-ARILO Y METODO, LAS COMPOSICIONES FARAMCEUTICAS QUE LOS CONTIENEN Y LOS INTERMEDIARIOS DE SINTESIS DEDICHOS COMPUESTOS
Argentina	040032	C-ARIL-GLUCOSIDOS COMO INHIBIDORES DE SGLT2 Y METODO
Austria	295848
Austria	353334
Australia	2003237886	C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD
Australia	781009

Supplementary Protection Certificates for XIGDUO XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2498758	LUC00152	Luxembourg		PRODUCT NAME: METFORMINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; SAXAGLIPTINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; DAPAGLIFLOZINE OU UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; AUTHORISATION NUMBER AND DATE: EU/1/19/1401 20191113
2139494	LUC00176	Luxembourg		PRODUCT NAME: SAXAGLIPTINE ET DAPAGLIFLOZINE; AUTHORISATION NUMBER AND DATE: EU/1/16/1108 20160719
1506211	588	Finland
1506211	122014000070	Germany		PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, WIE DURCH DAS GRUNDPATENT GESCHUETZT; REGISTRATION NO/DATE: EU/1/13/900 20140116
2498758	301040	Netherlands		PRODUCT NAME: METFORMINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; SAXAGLIPTINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1401 20191113
1506211	PA2014026,C1506211	Lithuania		PRODUCT NAME: DAPAGLIFLOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116

Last updated: July 30, 2026

Xigduo XR (dapagliflozin/metformin HCl ER) Investment Scenario and Fundamentals Analysis: Patents, Exclusivity, FDA Status, and Generic/Biosimilar Risk

Xigduo XR (dapagliflozin + metformin HCl extended-release) is a U.S.-market oral combination tied to the SGLT2 inhibitor and biguanide franchises. The investment case is dominated by (1) patent and regulatory exclusivity cliffs that govern generic entry timing, (2) payer and formulary pressure common to SGLT2 platforms, and (3) competitive dynamics versus other fixed-dose SGLT2/metformin ER and IR combinations. The risk profile is primarily “small-molecule generic economics” rather than biologics-style biosimilar dynamics.

This analysis is anchored on the product’s U.S. regulatory posture (FDA approval and Orange Book status), the typical exclusivity stack for combination products, and patent estate risks that translate into Paragraph IV litigation and settlement-driven entry dates.

---

What is Xigduo XR (dapagliflozin/metformin ER) and how does it generate revenue?

Quick answer: Xigduo XR is a fixed-dose oral therapy combining dapagliflozin (an SGLT2 inhibitor) with metformin HCl ER (extended-release) for type 2 diabetes. Revenue is driven by chronic use, formulary access, and share within the SGLT2 class and SGLT2/metformin combination basket.

Core fundamentals that affect investment returns

• Long-duration treatment economics: chronic therapy supports recurring demand if the product retains formulary position.
• SGLT2 class churn: share depends on class perceptions around CV/renal outcomes, tolerability, and payer preference.
• Combination convenience: fixed-dose regimens tend to improve adherence and reduce prescription burden versus separate agents.

Key value drivers to underwrite

• U.S. formulary penetration and rebate intensity relative to competing SGLT2/metformin products.
• Conversion from starter prescriptions to ongoing refills.
• Competitive pressure from newer SGLT2 agents and alternative fixed-dose combinations.
• Margin compression risk as generics enter the metformin backbone categories broadly (and if combination exclusivity falls).

---

What patents protect Xigduo XR, and how broad is the patent estate?

Quick answer: Xigduo XR is protected through a mix of composition-of-matter, formulation, and method-of-use patent families for dapagliflozin, metformin ER formulations, and fixed-dose combination claims. Exact claim coverage depends on Orange Book-listed patents tied to the NDA and the specific patent assignees and claim types.

How combination-product patent estates typically break down

1. Active ingredient families
   • Dapagliflozin composition-of-matter claims typically control broader SGLT2 market entry.
   • Metformin ER composition and related sustained-release matrix claims control formulation-specific substitution, though metformin generics are extensive in the market.
2. Fixed-dose combination claims
   • Combination ratio and dosage regimens can be protected through specific claim drafting.
3. Formulation and release mechanism
   • ER layer composition, polymer system, particle engineering, and dissolution profiles can block “non-infringing” formulation design-arounds if claims are specific and well supported.

Orange Book linkage matters for launch timing

Investment risk hinges on whether the Orange Book has unexpired, FDA-listed patents whose expiration or invalidation/expiration triggers FDA approval for generic entry (including via Paragraph IV).

---

When does Xigduo XR lose exclusivity in the U.S.?

Quick answer: Exclusivity timing is determined by (1) patent expiration for Orange Book-listed patents and (2) any remaining non-patent exclusivity for the NDA (expedited reviews, pediatric exclusivity, new clinical investigations, or other exclusivity grants where applicable). For combination products, the earliest controlling date typically governs practical generic timelines.

What sets the “first possible” generic entry date

• Earliest patent expiration among Orange Book-listed patents with claims covering the product.
• Any granted exclusivity that blocks ANDA approval even if patents expire.
• Whether patent litigation leads to a settlement triggering earlier or delayed entry.

Featured snippet take

The controlling exclusivity date for “Xigduo XR generic entry” is the earliest date when:

1. FDA can approve an ANDA (after exclusivity and patent status clear), and
2. no court injunction prevents launch under the applicable patent challenges.

---

What is the Orange Book status of Xigduo XR (dapagliflozin/metformin ER)?

Quick answer: Xigduo XR’s FDA patent landscape is reflected in the Orange Book listing for its NDA. The investable facts are the specific listed patents, their expiration dates, and whether they are controlled via bioavailability, formulation, or method-of-use claim sets.

Orange Book fields that drive investment models

• NDA holder and labeling strength (dosage forms and strengths).
• Patent numbers, listed drug substances/drug products, and listed claim types.
• Patent expiration and any regulatory exclusivity end dates.
• Whether there are multiple controlling patents per strength.

---

How many patents cover Xigduo XR, and which jurisdictions are most relevant for generic entry?

Quick answer: In the U.S., the number of controlling patents is best measured by the number of Orange Book-listed patents with active expiration windows. Jurisdictional risk mostly manifests in the U.S. via ANDA Paragraph IV litigation; outside the U.S., enforcement depends on national filings and local validity trends.

Geographic implications

• U.S. is the primary economic battleground for launch timing and market structure shifts.
• EU and UK enforcement typically matters for parallel export strategies but usually trails U.S. in timing impact on U.S. revenue.

---

Which companies are challenging Xigduo XR with Paragraph IV ANDAs?

Quick answer: Paragraph IV challenges are the key leading indicator of imminent generic entry. The market impact depends on whether challengers file early relative to the controlling patent expiration dates and whether litigation results in a settlement or adverse judgment.

Investment relevance

• Challenger count and their track record predict how aggressively the market will be undercut at launch.
• Settlement terms (carve-outs, delayed launch windows, agreed design-around acceptance) can reshape near-term revenue forecasts.

---

What patent litigation affects Xigduo XR, and what do settlement agreements imply for entry?

Quick answer: Xigduo XR’s generic entry risk hinges on the status of any ANDA patent infringement cases tied to Orange Book patents. Settlement agreements, when they occur, typically set a “launch on date X” schedule that can pull entry earlier than generic uncertainty models assume or delay entry if the case settles with longer standstill.

Model variables for litigation-driven entry

• Case filing date relative to patent expiration.
• Court rulings (invalidity, non-infringement, injunction scope).
• Settlement payment structure and permitted launch timelines.
• Strength-specific outcomes if only some dosages are cleared.

---

What formulations are protected by Xigduo XR patents (and can generics design around)?

Quick answer: Formulation patents often focus on ER release characteristics, matrix composition, and dissolution profiles that can be hard to replicate without triggering infringement or failing bioequivalence.

Typical design-around pathways

• Change polymer composition while retaining release and bioequivalence.
• Modify particle size distribution and manufacturing parameters to alter dissolution kinetics.
• Re-engineer matrix architecture to hit the same pharmacokinetic profile with different material composition.

Practical barrier

If claims are written broadly around “sustained-release” features without narrow limitations, design-around risk drops. If claims are narrow and anchored to specific ER matrix features, risk shifts to whether generic formulations can meet claim non-infringement while maintaining bioequivalence.

---

How does Xigduo XR compare with other SGLT2/metformin fixed-dose combinations?

Quick answer: Xigduo XR competes within a crowded SGLT2/metformin fixed-dose segment. The differentiators are dosing convenience, ER versus IR formulation preference, and payer-driven choice architecture.

Competitive dimensions that affect forecasting

• Formulary tier placement and preferred status.
• Copay/coverage management for branded SGLT2-based regimens.
• Switching cost: patients and prescribers may resist changes if GI tolerability differs between ER and IR.
• Clinical positioning: class-wide uptake depends on evidence around CV and renal outcomes, which tends to favor broad SGLT2 adoption regardless of the specific branded combination.

---

What are the FDA regulatory milestones for Xigduo XR (approval pathway and labeling scope)?

Quick answer: Xigduo XR is FDA-approved for type 2 diabetes indications, with labeling tied to dosing regimens for dapagliflozin and metformin ER. Regulatory milestones that matter to investment are mainly patent-linked ANDA approval feasibility and any label updates that expand or narrow use.

What matters for follow-on competitors

• Whether any supplemental approvals create new patent opportunities (new formulations, new strengths).
• Whether label changes affect “carve-out” opportunities for generic entrants (e.g., narrowed use patterns or dosage changes).

---

What generic entry risks exist for Xigduo XR (timing, dosing strengths, and ANDA economics)?

Quick answer: Generic entry risk is front-loaded around patent expiration windows listed in the Orange Book and the outcomes of any Paragraph IV disputes. For investors, the key is the earliest strength/date that a generic can launch in practice.

Entry scenario analysis framework

• Base case: earliest controlling patent expiry triggers ANDA launch after generic approval timeline.
• Downside case: longer litigation or injunction delays launch.
• Upside case: settlement accelerates entry or weak patents fall early.

Strength-specific risk

Combination products frequently have multiple controlling patents per strength. A generic may launch for some strengths first, leaving others protected longer, which can smooth revenue erosion rather than wiping out the entire SKU base.

---

Biosimilar risk for Xigduo XR: is it relevant?

Quick answer: No. Xigduo XR is a small-molecule drug combination, so the relevant generic pathway is ANDA, not biosimilar development.

---

Investment scenario: how to underwrite revenue exposure to patent and generic timelines

Quick answer: The practical underwriting approach treats Xigduo XR as an SGLT2/metformin branded asset exposed to near-term competition dynamics and medium-term generic erosion once Orange Book controls expire or are cleared via litigation and/or settlement.

Revenue exposure logic

• Stage 1 (protected): branded revenue supported by exclusivity and competitive differentiation.
• Stage 2 (litigation): revenue volatility increases as generic launch dates approach; payer contracting can shift to include anticipated generic price points.
• Stage 3 (entry): gross-to-net margin compression accelerates as payers move to lower-cost options and switch patterns increase.

How investors translate patent data into valuation

• Cash-flow modeling uses scenario-weighted launch timing and strength-level entry.
• Market share loss curves are anchored to historical SGLT2 class brand experiences and generic uptake patterns in chronic oral therapies.
• Margin sensitivity is tied to rebate intensity and wholesaler channel inventory behavior around launch.

---

Key takeaways

• Xigduo XR’s investment outcome is driven by Orange Book-listed patent expirations and any Paragraph IV litigation outcomes that set practical generic launch dates.
• The primary competitor threat is small-molecule ANDA entry and payer-driven substitution into alternative SGLT2/metformin fixed-dose ER products.
• Biosimilar risk is not applicable; the correct risk lens is patent and generic economics for small molecules.
• Underwrite using strength-specific Orange Book controls, not only the earliest overall patent date.

---

FAQs

1) What patents typically control fixed-dose SGLT2/metformin ER combinations like Xigduo XR?

Typically, control comes from dapagliflozin-related composition families, formulation/ER release patents covering matrix design, and combination-specific dosage regimen claims tied to the fixed-dose product.

2) How do Paragraph IV ANDA challenges change Xigduo XR’s generic launch forecast?

They create litigation-driven launch calendars. If courts invalidate patents or non-infringement is sustained, or if settlement permits early entry, launch can occur sooner than “patent-only” expiration modeling suggests.

3) Does Xigduo XR face different risks for each dosage strength?

Yes. Orange Book listings can be strength-specific, so generic entry may occur first for some strengths, delaying complete revenue erosion.

4) What is the most important regulatory event for generic approval of Xigduo XR?

ANDA approval depends on clearing patent and exclusivity barriers tied to the NDA and Orange Book-listed patents, plus standard FDA chemistry and bioequivalence requirements.

5) Can generics design around ER formulation patents for Xigduo XR?

They may, but feasibility hinges on whether claims are narrowly tied to specific ER matrix attributes or drafted broadly to capture release characteristics that are harder to reproduce without infringement.

---

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.